Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Akebia Therapeutics, Inc. (AKBA : NSDQ)

• Company Description    Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. Number of Employees: 181

• Price / Volume Information    Yesterday's Closing Price: $2.95 Daily Weekly Monthly 20 Day Moving Average: 3,812,911 shares Shares Outstanding: 265.14 (millions) Market Capitalization: $782.18 (millions) Beta: 1.02 52 Week High: $4.08 52 Week Low: $1.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.33% -11.91% 12 Week -17.13% -24.73% Year To Date 55.26% 40.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 245 FIRST STREET SUITE 1100 - CAMBRIDGE,MA 02142 USA ph: 617-871-2098 fax: 617-871-2099 ir@akebia.com http://www.akebia.com

• General Corporate Information    Officers John P. Butler - President and Chief Executive Officer Adrian Adams - Chairperson Erik J. Ostrowski - Senior Vice President; Chief Financial Officer and Richard C. Malabre - Senior Vice President; Chief Accounting Officer Ron Frieson - Director Peer Information Akebia Therapeutics, Inc. (GSAC) Akebia Therapeutics, Inc. (CASI) Akebia Therapeutics, Inc. (ALCD.) Akebia Therapeutics, Inc. (OMNN) Akebia Therapeutics, Inc. (CGPI.) Akebia Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 00972D105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 265.14 Most Recent Split Date: (:1) Beta: 1.02 Market Capitalization: $782.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.01 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.00 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 26.51 Price/Cash Flow: - Price / Sales: 3.84 EPS Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: -100.00% Sales Growth vs. Year Ago Period: 43.13% vs. Previous Quarter: 8.96% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - -13.47 03/31/25 - -18.92 12/31/24 - -31.78 Current Ratio 06/30/25 - 1.98 03/31/25 - 2.23 12/31/24 - 1.41 Quick Ratio 06/30/25 - 1.84 03/31/25 - 2.02 12/31/24 - 1.21 Operating Margin 06/30/25 - -17.91 03/31/25 - -24.51 12/31/24 - -43.33 Net Margin 06/30/25 - -17.91 03/31/25 - -24.51 12/31/24 - -43.33 Pre-Tax Margin 06/30/25 - -17.91 03/31/25 - -24.51 12/31/24 - -43.33 Book Value 06/30/25 - 0.11 03/31/25 - 0.09 12/31/24 - -0.23 Inventory Turnover 06/30/25 - 2.85 03/31/25 - 2.95 12/31/24 - 2.93 Debt-to-Equity 06/30/25 - 1.61 03/31/25 - 1.89 12/31/24 - - Debt-to-Capital 06/30/25 - 61.69 03/31/25 - 65.42 12/31/24 - -

Powered by Zacks Investment Research ©